Cargando…

Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada

Recent evidence shows that COVID-19 infection does not have a worse prognosis in patients with immune-mediated inflammatory diseases (IMID), although they develop a worse response to vaccination. Objective To compare the incidence of COVID-19 and clinical features in patients with IMID between the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobo-Rodriguez, C, López-Calleja, A.M, de los Ríos, P Morales, Sánchez-Vázquez, S, Molinero-Sampedro, A, López-Esteban, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier España, S.L.U. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070772/
https://www.ncbi.nlm.nih.gov/pubmed/37361904
http://dx.doi.org/10.1016/j.reuma.2023.02.008
_version_ 1785019064792383488
author Lobo-Rodriguez, C
López-Calleja, A.M
de los Ríos, P Morales
Sánchez-Vázquez, S
Molinero-Sampedro, A
López-Esteban, A
author_facet Lobo-Rodriguez, C
López-Calleja, A.M
de los Ríos, P Morales
Sánchez-Vázquez, S
Molinero-Sampedro, A
López-Esteban, A
author_sort Lobo-Rodriguez, C
collection PubMed
description Recent evidence shows that COVID-19 infection does not have a worse prognosis in patients with immune-mediated inflammatory diseases (IMID), although they develop a worse response to vaccination. Objective To compare the incidence of COVID-19 and clinical features in patients with IMID between the first and sixth waves. Method Prospective observational study of two cohorts of IMID patients diagnosed with COVID-19. First cohort March to May 2020, and second cohort December/2021 to February/2022. Sociodemographic and clinical variables were collected and, in the second cohort, COVID-19 vaccination status. Statistical analysis established differences in characteristics and clinical course between the two cohorts. Results In total, 1627 patients were followed up, of whom 77 (4.60%) contracted COVID-19 during the first wave and 184 in the sixth wave (11.3%). In the sixth wave, there were fewer hospitalisations, intensive care unit admissions, and deaths than in the first wave (p=.000) and 180 patients (97.8%) had at least one dose of vaccine. Conclusion Early detection and vaccination have prevented the occurrence of serious complications.
format Online
Article
Text
id pubmed-10070772
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-100707722023-04-04 Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada Lobo-Rodriguez, C López-Calleja, A.M de los Ríos, P Morales Sánchez-Vázquez, S Molinero-Sampedro, A López-Esteban, A Reumatol Clin Article Recent evidence shows that COVID-19 infection does not have a worse prognosis in patients with immune-mediated inflammatory diseases (IMID), although they develop a worse response to vaccination. Objective To compare the incidence of COVID-19 and clinical features in patients with IMID between the first and sixth waves. Method Prospective observational study of two cohorts of IMID patients diagnosed with COVID-19. First cohort March to May 2020, and second cohort December/2021 to February/2022. Sociodemographic and clinical variables were collected and, in the second cohort, COVID-19 vaccination status. Statistical analysis established differences in characteristics and clinical course between the two cohorts. Results In total, 1627 patients were followed up, of whom 77 (4.60%) contracted COVID-19 during the first wave and 184 in the sixth wave (11.3%). In the sixth wave, there were fewer hospitalisations, intensive care unit admissions, and deaths than in the first wave (p=.000) and 180 patients (97.8%) had at least one dose of vaccine. Conclusion Early detection and vaccination have prevented the occurrence of serious complications. Published by Elsevier España, S.L.U. 2023-04-04 /pmc/articles/PMC10070772/ /pubmed/37361904 http://dx.doi.org/10.1016/j.reuma.2023.02.008 Text en © 2023 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lobo-Rodriguez, C
López-Calleja, A.M
de los Ríos, P Morales
Sánchez-Vázquez, S
Molinero-Sampedro, A
López-Esteban, A
Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title_full Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title_fullStr Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title_full_unstemmed Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title_short Comparación entre la primera y la sexta ola de la pandemia por el coronavirus SARS-COV-2 en pacientes con enfermedad inmunomediada
title_sort comparación entre la primera y la sexta ola de la pandemia por el coronavirus sars-cov-2 en pacientes con enfermedad inmunomediada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070772/
https://www.ncbi.nlm.nih.gov/pubmed/37361904
http://dx.doi.org/10.1016/j.reuma.2023.02.008
work_keys_str_mv AT loborodriguezc comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada
AT lopezcallejaam comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada
AT delosriospmorales comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada
AT sanchezvazquezs comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada
AT molinerosampedroa comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada
AT lopezestebana comparacionentrelaprimeraylasextaoladelapandemiaporelcoronavirussarscov2enpacientesconenfermedadinmunomediada